Biomarin (BMRN) rockets 29% after saying that its GALNS drug met its main target in a Phase III...

|By:, SA News Editor

Biomarin (BMRN) rockets 29% after saying that its GALNS drug met its main target in a Phase III trial of improving the walking ability of patients with the rare genetic disorder of Morquio A Syndrome. The drug is seen as the most important in BioMarin's pipeline, with the potential to double its revenue. (PR)